King Files 20 Levoxyl Patent Applications; Sales Up 65% to $27 Mil. In Q3
Executive Summary
King has filed 20 patent applications for Levoxyl (levothyroxine) to extend exclusivity for the thyroid hormone product, the company said during an Oct. 29 earnings call
You may also be interested in...
From The Quarterly Conference Calls
Geneva Augmentin generic reserve: Geneva's generic amoxicillin/clavulanate earnings are being placed in a reserve in the event the company loses GlaxoSmithKline's appeal of the Augmentin patent lawsuit, Novartis CEO Daniel Vasella said July 22. "We will book sales, but we will not book the earnings out of this product but put them in a reserve," the exec said. "The additional exposure should we - against all odds - lose the appeal next year, would be an amount which we can digest, I would say, rather easily." GSK is appealing a May 22 ruling in Geneva's favor; a decision could come as early as January (1"The Pink Sheet" May 27, p. 20). Geneva launched amoxicillin generics in June...
From The Quarterly Conference Calls
Geneva Augmentin generic reserve: Geneva's generic amoxicillin/clavulanate earnings are being placed in a reserve in the event the company loses GlaxoSmithKline's appeal of the Augmentin patent lawsuit, Novartis CEO Daniel Vasella said July 22. "We will book sales, but we will not book the earnings out of this product but put them in a reserve," the exec said. "The additional exposure should we - against all odds - lose the appeal next year, would be an amount which we can digest, I would say, rather easily." GSK is appealing a May 22 ruling in Geneva's favor; a decision could come as early as January (1"The Pink Sheet" May 27, p. 20). Geneva launched amoxicillin generics in June...
King Altace Physician Promotion Emphasized For 2001; DTC Delayed To 2002
King Pharmaceuticals will dedicate its entire $90 mil. Altace marketing campaign to physician-directed promotions following deferment of the ACE inhibitor's DTC advertising campaign.